SPECT- and PET-based patient-tailored treatment in neuroendocrine tumors: A comprehensive multidisciplinary team approach

R. A. Werner, Christina Bluemel, M. Lassmann, T. Kudlich, T. Higuchi, Egesta Lopci, M. Allen-Auerbach, Patrick M. Colletti, Domenico Rubello, M. C. Zatelli, Ken Herrmann

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The overexpression of somatostatin receptors on the tumor cell surface of neuroendocrine tumors (NETs) detected by multimodal functional imaging modalities such as SPECTand PET tracers constitutes a therapeutic option using targeting radiolabeled compounds. We will introduce the theranostic concept in general, explain in more detail its development in NETs, and discuss available SPECT and PET tracers regarding their potential for diagnostic imaging, visualization of target expression, and treatment tailoring.Moreover,wewill discuss the currently available peptide receptor radionuclide therapy principles and compare them to previously published studies. Finally,wewill discusswhich newconcepts will most likely influence the theranostic treatment approach in NETs in the future.

Original languageEnglish
Pages (from-to)e271-e277
JournalClinical Nuclear Medicine
Volume40
Issue number5
DOIs
Publication statusPublished - May 22 2015

Fingerprint

Neuroendocrine Tumors
Single-Photon Emission-Computed Tomography
Multimodal Imaging
Somatostatin Receptors
Peptide Receptors
Diagnostic Imaging
Therapeutics
Radioisotopes
Neoplasms
Theranostic Nanomedicine

Keywords

  • neuroendocrine tumors
  • PET-based patient-tailored
  • SPECT-based patient-tailored
  • tailored treatment
  • team approach

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

SPECT- and PET-based patient-tailored treatment in neuroendocrine tumors : A comprehensive multidisciplinary team approach. / Werner, R. A.; Bluemel, Christina; Lassmann, M.; Kudlich, T.; Higuchi, T.; Lopci, Egesta; Allen-Auerbach, M.; Colletti, Patrick M.; Rubello, Domenico; Zatelli, M. C.; Herrmann, Ken.

In: Clinical Nuclear Medicine, Vol. 40, No. 5, 22.05.2015, p. e271-e277.

Research output: Contribution to journalArticle

Werner, RA, Bluemel, C, Lassmann, M, Kudlich, T, Higuchi, T, Lopci, E, Allen-Auerbach, M, Colletti, PM, Rubello, D, Zatelli, MC & Herrmann, K 2015, 'SPECT- and PET-based patient-tailored treatment in neuroendocrine tumors: A comprehensive multidisciplinary team approach', Clinical Nuclear Medicine, vol. 40, no. 5, pp. e271-e277. https://doi.org/10.1097/RLU.0000000000000729
Werner, R. A. ; Bluemel, Christina ; Lassmann, M. ; Kudlich, T. ; Higuchi, T. ; Lopci, Egesta ; Allen-Auerbach, M. ; Colletti, Patrick M. ; Rubello, Domenico ; Zatelli, M. C. ; Herrmann, Ken. / SPECT- and PET-based patient-tailored treatment in neuroendocrine tumors : A comprehensive multidisciplinary team approach. In: Clinical Nuclear Medicine. 2015 ; Vol. 40, No. 5. pp. e271-e277.
@article{e1a7a4fb5b4c40fab7087771475d8c34,
title = "SPECT- and PET-based patient-tailored treatment in neuroendocrine tumors: A comprehensive multidisciplinary team approach",
abstract = "The overexpression of somatostatin receptors on the tumor cell surface of neuroendocrine tumors (NETs) detected by multimodal functional imaging modalities such as SPECTand PET tracers constitutes a therapeutic option using targeting radiolabeled compounds. We will introduce the theranostic concept in general, explain in more detail its development in NETs, and discuss available SPECT and PET tracers regarding their potential for diagnostic imaging, visualization of target expression, and treatment tailoring.Moreover,wewill discuss the currently available peptide receptor radionuclide therapy principles and compare them to previously published studies. Finally,wewill discusswhich newconcepts will most likely influence the theranostic treatment approach in NETs in the future.",
keywords = "neuroendocrine tumors, PET-based patient-tailored, SPECT-based patient-tailored, tailored treatment, team approach",
author = "Werner, {R. A.} and Christina Bluemel and M. Lassmann and T. Kudlich and T. Higuchi and Egesta Lopci and M. Allen-Auerbach and Colletti, {Patrick M.} and Domenico Rubello and Zatelli, {M. C.} and Ken Herrmann",
year = "2015",
month = "5",
day = "22",
doi = "10.1097/RLU.0000000000000729",
language = "English",
volume = "40",
pages = "e271--e277",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - SPECT- and PET-based patient-tailored treatment in neuroendocrine tumors

T2 - A comprehensive multidisciplinary team approach

AU - Werner, R. A.

AU - Bluemel, Christina

AU - Lassmann, M.

AU - Kudlich, T.

AU - Higuchi, T.

AU - Lopci, Egesta

AU - Allen-Auerbach, M.

AU - Colletti, Patrick M.

AU - Rubello, Domenico

AU - Zatelli, M. C.

AU - Herrmann, Ken

PY - 2015/5/22

Y1 - 2015/5/22

N2 - The overexpression of somatostatin receptors on the tumor cell surface of neuroendocrine tumors (NETs) detected by multimodal functional imaging modalities such as SPECTand PET tracers constitutes a therapeutic option using targeting radiolabeled compounds. We will introduce the theranostic concept in general, explain in more detail its development in NETs, and discuss available SPECT and PET tracers regarding their potential for diagnostic imaging, visualization of target expression, and treatment tailoring.Moreover,wewill discuss the currently available peptide receptor radionuclide therapy principles and compare them to previously published studies. Finally,wewill discusswhich newconcepts will most likely influence the theranostic treatment approach in NETs in the future.

AB - The overexpression of somatostatin receptors on the tumor cell surface of neuroendocrine tumors (NETs) detected by multimodal functional imaging modalities such as SPECTand PET tracers constitutes a therapeutic option using targeting radiolabeled compounds. We will introduce the theranostic concept in general, explain in more detail its development in NETs, and discuss available SPECT and PET tracers regarding their potential for diagnostic imaging, visualization of target expression, and treatment tailoring.Moreover,wewill discuss the currently available peptide receptor radionuclide therapy principles and compare them to previously published studies. Finally,wewill discusswhich newconcepts will most likely influence the theranostic treatment approach in NETs in the future.

KW - neuroendocrine tumors

KW - PET-based patient-tailored

KW - SPECT-based patient-tailored

KW - tailored treatment

KW - team approach

UR - http://www.scopus.com/inward/record.url?scp=84928421672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928421672&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000000729

DO - 10.1097/RLU.0000000000000729

M3 - Article

C2 - 25642915

AN - SCOPUS:84928421672

VL - 40

SP - e271-e277

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 5

ER -